Roivant Sciences (NASDAQ:ROIV) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Roivant Sciences (NASDAQ:ROIV) posted its earnings results on Monday. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04, Zacks reports. Roivant Sciences had a net margin of 3,827.42% and a negative return on equity of 14.65%.

Roivant Sciences Trading Up 0.2 %

Shares of Roivant Sciences stock opened at $10.89 on Monday. Roivant Sciences has a twelve month low of $9.76 and a twelve month high of $13.06. The firm has a market capitalization of $7.93 billion, a PE ratio of 1.93 and a beta of 1.25. The firm’s 50-day moving average price is $11.51 and its 200 day moving average price is $11.60.

Analyst Ratings Changes

A number of research analysts have weighed in on ROIV shares. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a report on Thursday, January 30th. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $17.93.

Insiders Place Their Bets

In other Roivant Sciences news, Director Sciences Ltd. Roivant bought 16,845,010 shares of Roivant Sciences stock in a transaction dated Monday, January 13th. The stock was acquired at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the transaction, the director now directly owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the completion of the transaction, the chief operating officer now directly owns 732,294 shares in the company, valued at approximately $8,260,276.32. This represents a 12.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,942,629 shares of company stock worth $23,034,486. Corporate insiders own 7.90% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.